GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HAEMATO AG (XTER:HAEK) » Definitions » Institutional Ownership

HAEMATO AG (XTER:HAEK) Institutional Ownership : 0.02% (As of May. 27, 2024)


View and export this data going back to 2005. Start your Free Trial

What is HAEMATO AG Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, HAEMATO AG's institutional ownership is 0.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, HAEMATO AG's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, HAEMATO AG's Float Percentage Of Total Shares Outstanding is 0.00%.


HAEMATO AG Institutional Ownership Historical Data

The historical data trend for HAEMATO AG's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HAEMATO AG Institutional Ownership Chart

HAEMATO AG Historical Data

The historical data trend for HAEMATO AG can be seen below:

2023-04-30 2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31
Institutional Ownership 0.62 0.62 0.62 0.62 0.62 0.62 0.62 0.13 0.02 0.02

HAEMATO AG Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


HAEMATO AG (XTER:HAEK) Business Description

Traded in Other Exchanges
Address
Lilienthalstrasse 5c, Schonefeld, DEU, D-12529
HAEMATO AG is a Germany based pharmaceutical company. It provides pharmaceuticals for the care of chronically ill people. The firm is engaged in the sale of generic and EU (European countries) import drugs. It is focused on patented and non-patented medicinal products. The company product portfolio includes human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), neurology, oncology, rheumatology, and urology. Geographically, it operates only in Germany.

HAEMATO AG (XTER:HAEK) Headlines

No Headlines